Neela Patel Email & Phone Number

Belmont, Ca, Us

Alameda, California, Us

Seattle, Wa, Us

Seattle, Washington, Us

Led two major transactions • Spin-out from Good Therapeutics to Bonum Therapeutics of employees, platform, and all programs except PD1-IL2• Acquisition of Good Therapeutics (PD1-IL2 program) by Roche for $250 million upfront plus milestonesProvided strategic leadership for• Corporate communications, including media presence and website• Project and alliance management

Bothell, Washington, Us

Developed and executed in-licensing strategy to augment and diversify pre-clinical and clinical portfolio with assets & technologies, and clinical combination trials• Sourced and executed deals that will account for 40% of new INDs in 2021-2022• Evaluate ~350 preclinical opportunities and ~100 clinical assets annually; maintain flow of 15-20 MTAs to enable sustainable portfolio; lead term sheet and contract negotiations.Leadership• Selected for Seattle Genetics’ Leadership Academy (16 participants out of 1200 employees)• Promoted culture open to external opportunities by collaborating with research and clinical leadership to evaluate and address gaps in pipeline flow• Brought company into new technical areas through licensing and collaborations

• Sourced and evaluated 300-400 opportunities per year for licensing, investment, or acquisition with confidential review of 25-50 annually; opportunities included technology platforms, and assets from discovery through mid-clinical stage• Oversaw technical teams from initial evaluation through due diligence on selected opportunities; crafted appropriate business structure based on science; presented diligence findings to R&D leadership team• Catalyzed and managed annual oncology strategic planning process for five years, resulting in identification of prioritized focus areas and appropriate internal/external tactics• Managed biweekly licensing review team with therapeutic area leaders from research, development, legal, and transaction groups• 20+ executed deals over seven years, including multi-target licensing agreements with competitive upfront/milestones/sales milestones/royalties, drug discovery and development consortia, biotech collaborations to access key technologies or expertise, and academic collaborations

Abbott Park, Illinois, Us

Augmented Abbvie discovery pipeline with external target/drugs and technologies• Regional scout for western US: identified academic and biotech collaborative opportunities in oncology, neuroscience, immunology, renal, biologics and drug discovery technologies• Therapy area liaison for oncology. Assessed all incoming opportunities worldwide for technical robustness and strategic fit (>300/yr). Conducted proactive outreach globally to institutes, biotechs, consortia. Led technical diligence, including generation of collaboration models and workplans• Enabled focus areas: epigenetics with SGC participation and Epitherapeutics multi-target deal; antibody-drug conjugates by sourcing and executing agreements with linker-toxin and conjugation technologies; translational medicine with agreements to access databases, animal models, and IMI consortia; other early stage areas with academic collaborations• Abbott non-pharma divisions: contributed leads for diagnostics and medical device divisions, generated evaluations of oncology and ophthalmology leads for corporate venture

Us

Developed strategy for pipeline with head of chemistry: number and type of projects, milestones, resources required, forecasting and management of research budget (~$6M total annual budget, $3M for studies conducted at CROs). Led project licensed to Verastem in 2011 for clinical development.• Oversaw establishment of new molecular and cell biology labs• Assembled network of CROs to perform PK/ADME and efficacy experiments• Conducted pre-clinical diligence on licensing opportunities: 200+ oncology opportunities evaluated, including competitive research, relative ranking of assets, and recommendations for terms sheets

South San Francisco, California, Us

Established and directed pre-clinical project management for internal and in-licensed projects (small molecule and biologics) through IND filing • Staffed, developed, and led project management group for Genentech’s late pre-clinical portfolioo Built and managed department of 9 pre-clinical project managers. Recruited and integrated 8 new staff members in 18 monthso Coached project managers to facilitate decision making and conflict resolution at project team and/or management levelo In two years, 5 INDs filed and achieved steady state portfolio of 15 projects• Prepared and delivered overall pre-clinical portfolio views to senior management, identified common themes from issues and instituted system wide solutions• Developed and implemented basic portfolio tracking for pre-clinical programs, rolling forecast for potential new projects from research, and capacity planning for 12-18 month horizon• Ensured identification of risks and mitigation plans for each project

New York, New York, Us

• Therapy Area Leadership, Ophthalmologyo Ophthalmology Therapy Area Core Team Member (5 member team) o Developed strategy for therapy area, secured management approval for new TA. Team subsequently responsible for ophthalmology research portfolio• Ophthalmology Discovery Licensing Team Member: identified and evaluated in-licensing opportunities from scientific and strategic perspective• Project Team Leader: VEGFR inhibitors for retinal disease• Management: supervised cell biology group for small molecule discovery. Functional responsibilities included cell-based phenotypic and target modulation assays, and mechanism of action studies. Project-based responsibilities included mentoring oncology team leaders to ensure execution and delivery of milestones.

Project Team LeaderNew target identification for osteoporosis• Led multi-site team (Palo Alto, Antwerp, Basel) to identify human gene involved in bone formation by positional cloningSmall molecule antagonists of a G protein-coupled receptor for osteoporosis• Supervised team: HTS through in vivo proof of concept for target GPCRo Developed structure-activity relationship of lead compound with chemisto Designed experiments and performed data analysis to assess in vivo efficacy of compounds

Us

Phd, Molecular Biology

Bs/Ba, Biology/Humanities